STOK - Stoke Therapeutics, Inc.

QQQ $ 611.98 $ 0.42 (0.07 %)

DIA $ 469.93 $ 2.81 (0.6 %)

SPY $ 672.30 $ 0.81 (0.12 %)

TLT $ 92.01 $ 0.02 (0.02 %)

GLD $ 379.17 $ -7.47 (-1.93 %)

Previous Close

$ 34.65

Open

$ 34.18

Bid

$ 34.18 x 14

Ask

$ 34.24 x 2

Day's Range

$ 33.35 - $ 34.73

52 Week Range

$ 5.35 - $ 38.69

Volume

1,027,465

Average Volume

Market Cap

1.9B

Beta (5Y Monthly)

$ 1.46

PE Ratio (TTM)

$ 36.18

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-12-2025	06-30-2025	10-Q
2	05-13-2025	03-31-2025	10-Q
3	03-18-2025	12-31-2024	10-K
4	11-05-2024	09-30-2024	10-Q
5	08-07-2024	06-30-2024	10-Q
6	05-06-2024	03-31-2024	10-Q
7	03-25-2024	12-31-2023	10-K
8	11-07-2023	09-30-2023	10-Q
9	08-07-2023	06-30-2023	10-Q
10	05-04-2023	03-31-2023	10-Q
11	03-06-2023	12-31-2022	10-K
12	11-14-2022	09-30-2022	10-Q
13	08-08-2022	06-30-2022	10-Q
14	05-10-2022	03-31-2022	10-Q
15	03-10-2022	12-31-2021	10-K
16	11-08-2021	09-30-2021	10-Q
17	08-10-2021	06-30-2021	10-Q
18	05-10-2021	03-31-2021	10-Q
19	03-09-2021	12-31-2020	10-K
20	11-12-2020	09-30-2020	10-Q
21	08-10-2020	06-30-2020	10-Q
22	05-15-2020	03-31-2020	10-Q
23	03-23-2020	12-31-2019	10-K
24	11-12-2019	09-30-2019	10-Q
25	08-14-2019	06-30-2019	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Stoke Therapeutics Unveils Two-Year Data O...
10/20/2025 11:36:16

Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the bod...

What 4 Analyst Ratings Have To Say About S...
10/10/2025 22:01:27

Needham Maintains Buy on Stoke Therapeutic...
10/10/2025 10:22:26

Needham analyst Joseph Stringer maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy and raises the price target from $22 t...

Biogen And Stoke Announce Phase 3 Zorevune...
10/09/2025 20:32:46

– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improveme...

Stoke Therapeutics Names Ian F. Smith CEO
10/06/2025 11:36:29

Leader with Long Track Record in Building World-Class Biopharma Companies and Driving Late-Stage Development and Commercial Exe...

Reported Earlier, Biogen And Stoke Highlig...
09/03/2025 06:55:31

– Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continue...

Reported Earlier: Biogen And Stoke Therape...
09/02/2025 13:56:46

– Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continue...

Biogen And Stoke Therapeutics Announced Pr...
08/25/2025 11:10:57

Where Stoke Therapeutics Stands With Analysts
08/13/2025 20:01:40

Chardan Capital Maintains Buy on Stoke The...
08/13/2025 16:05:17

Chardan Capital analyst Rudy Li maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $24 price target.

Wedbush Maintains Outperform on Stoke Ther...
08/13/2025 14:30:48

Wedbush analyst Laura Chico maintains Stoke Therapeutics (NASDAQ:STOK) with a Outperform and raises the price target from $1...

Stoke Therapeutics Q2 EPS $(0.40) Beats $(...
08/12/2025 20:02:05

Stoke Therapeutics (NASDAQ:STOK) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(...

Earnings Scheduled For August 12, 2025
08/12/2025 08:32:28

A Look Ahead: Stoke Therapeutics's Earning...
08/11/2025 16:03:00

Stoke Therapeutics And Biogen Announced Th...
08/11/2025 11:05:22

Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment perio...

12 Health Care Stocks Moving In Tuesday's ...
07/22/2025 21:06:00

dr-horton-iqvia-holdings-northrop-grumman-and-other-big-stocks-moving-higher-on-tuesday

D.R. Horton, IQVIA Holdings, Northrop Grum...
07/22/2025 14:23:12

this-verint-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-friday

This Verint Analyst Begins Coverage On A B...
07/18/2025 13:17:15

Jefferies Initiates Coverage On Stoke Ther...
07/18/2025 11:50:34

Jefferies analyst Andrew Tsai initiates coverage on Stoke Therapeutics (NASDAQ:STOK) with a Buy rating and announces Price T...

Stoke Therapeutics And Biogen Announce Pre...
07/10/2025 11:02:10